Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma

Journal of Controlled Release

Volumn 259, Issue , 2017, Pages 136-148

  Guo, Hui ^a,b   Xu, Weiguo ^a   Chen, Jinjin ^a   Yan, Lesan ^a   Ding, Jianxun ^a   Hou, Yuchuan ^b   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Chemotherapy; Mucoadhesion; Orthotopic bladder carcinoma; Penetrability; Positive charge; Reduction responsive polypeptide nanogel

Indexed keywords

AMINO ACIDS; CELLS; CHEMOTHERAPY; DISEASES; DRUG PRODUCTS; ENZYME INHIBITION; POLYPEPTIDES;

BLADDER CARCINOMA; MUCOADHESION; NANOGELS; PENETRABILITY; POSITIVE CHARGES;

NANOSTRUCTURED MATERIALS;

10 HYDROXYCAMPTOTHECIN; CYCLINE; DISULFIDE; DRUG CARRIER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(LEVO LYSINE)POLY(LEVO PHENYLALANINE CO LEVO CYSTINE); POLYPEPTIDE; UNCLASSIFIED DRUG; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; NANOMATERIAL; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER CELL LINE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG PENETRATION; DRUG RELEASE; DRUG SYNTHESIS; GEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; MOUSE; MUCOADHESION; NANOGEL; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ADHESION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; MUCOSA; TUMOR CELL LINE;

ADHESIVENESS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG CARRIERS; DRUG LIBERATION; GELS; HUMANS; MALE; MICE, INBRED BALB C; MUCOUS MEMBRANE; NANOSTRUCTURES; PEPTIDES; TISSUE DISTRIBUTION; URINARY BLADDER NEOPLASMS;

EID: 85009250435     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.12.041     Document Type: Article

References (49)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
2. Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., Stein, K.D., Alteri, R., Jemal, A., Cancer treatment and survivorship statistics, 2016. Ca-Cancer J. Clin. 66 (2016), 271–289.
3. Chavan, S., Bray, F., Lortet-Tieulent, J., Goodman, M., Jemal, A., International variations in bladder cancer incidence and mortality. Eur. Urol. 66 (2014), 59–73.
4. Casey, R.G., Catto, J.W.F., Cheng, L., Cookson, M.S., Herr, H., Shariat, S., Witjes, J.A., Black, P.C., Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review. Eur. Urol. 67 (2015), 876–888.
5. Jarvinen, R., Marttila, T., Kaasinen, E., Rintala, E., Aaltomaa, S., Kallio, J., Liukkonen, T., Puolakka, V.M., Seppanen, M., Tuhkanen, K., Vaarala, M., Viitanen, J., Bostrom, P.J., FinnBladder, G., Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly Bacillus Calmette-Guerin (BCG) or alternating BCG and interferon-α 2b instillations: Prospective randomised FinnBladder-4 study. Eur. Urol. 68 (2015), 611–617.
6. Kaufman, D.S., Shipley, W.U., Feldman, A.S., Bladder cancer. Lancet 374 (2009), 239–249.
7. Cambier, S., Sylvester, R.J., Collette, L., Gontero, P., Brausi, M.A., van Andel, G., Kirkels, W.J., Da Silva, F.C., Oosterlinck, W., Prescott, S., Kirkali, Z., Powell, P.H., de Reijke, T.M., Turkeri, L., Collette, S., Oddens, J., EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guerin. Eur. Urol. 69 (2016), 60–69.
8. Lu, S., Neoh, K.G., Kang, E.T., Mahendran, R., Chiong, E., Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. Eur. J. Pharm. Sci. 72 (2015), 57–68.
9. Rieger, C., Kunhardt, D., Kaufmann, A., Schendel, D., Huebner, D., Erdmann, K., Propping, S., Wirth, M.P., Schwenzer, B., Fuessel, S., Characterization of different carbon nanotubes for the development of a mucoadhesive drug delivery system for intravesical treatment of bladder cancer. Int. J. Pharm. 479 (2015), 357–363.
10. Joraku, A., Homhuan, A., Kawai, K., Yamamoto, T., Miyazaki, J., Kogure, K., Yano, I., Harashima, H., Akaza, H., Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-GuErin. BJU Int. 103 (2009), 686–693.
11. Nakamura, T., Fukiage, M., Higuchi, M., Nakaya, A., Yano, I., Miyazaki, J., Nishiyama, H., Akaza, H., Ito, T., Hosokawa, H., Nakayama, T., Harashima, H., Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J. Control. Release 176 (2014), 44–53.
12. Mugabe, C., Hadaschik, B.A., Kainthan, R.K., Brooks, D.E., So, A.I., Gleave, M.E., Burt, H.M., Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int. 103 (2009), 978–986.
13. Senyigit, Z.A., Karavana, S.Y., Ilem-Ozdemir, D., Caliskan, C., Waldner, C., Sen, S., Bernkop-Schnurch, A., Baloglu, E., Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan/poloxamer gels as carriers. Int. J. Nanomedicine 10 (2015), 6493–6507.
14. GuhaSarkar, S., Banerjee, R., Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. J. Control. Release 148 (2010), 147–159.
15. Yan, L., Crayton, S.H., Thawani, J.P., Amirshaghaghi, A., Tsourkas, A., Cheng, Z., A pH-responsive drug-delivery platform based on glycol chitosan-coated liposomes. Small 11 (2015), 4870–4874.
16. Lu, S., Xu, L., Kang, E.T., Mahendran, R., Chiong, E., Neoh, K.G., Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. Eur. J. Pharm. Sci. 84 (2016), 103–115.
17. Kos, M.K., Bogataj, M., Veranic, P., Mrhar, A., Permeability of pig urinary bladder wall: Time and concentration dependent effect of chitosan. Biol. Pharm. Bull. 29 (2006), 1685–1691.
18. Lele, B.S., Hoffman, A.S., Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydride-drug linkages. J. Control. Release 69 (2000), 237–248.
19. Wang, H., Feng, J., Liu, G., Chen, B., Jiang, Y., Xie, Q., In vitro and in vivo anti-tumor efficacy of 10-hydroxycamptothecin polymorphic nanoparticle dispersions: Shape- and polymorph-dependent cytotoxicity and delivery of 10-hydroxycamptothecin to cancer cells. Nanomed.: Nanotechnol., Biol. Med. 12 (2016), 881–891.
20. Liu, Y., An, S., Li, J., Kuang, Y., He, X., Guo, Y., Ma, H., Zhang, Y., Ji, B., Jiang, C., Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice. Biomaterials 80 (2016), 33–45.
21. Shin, M.C., Zhang, J., Min, K.A., Lee, K., Byun, Y., David, A.E., He, H., Yang, V.C., Cell-penetrating peptides: Achievements and challenges in application for cancer treatment. J. Biomed. Mater. Res. A 102 (2014), 575–587.
22. Shi, C., Guo, X., Qu, Q., Tang, Z., Wang, Y., Zhou, S., Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles. Biomaterials 35 (2014), 8711–8722.
23. Huang, K., Shi, B., Xu, W., Ding, J., Yang, Y., Liu, H., Zhuang, X., Chen, X., Reduction-responsive polypeptide nanogel delivers antitumor drug for improved efficacy and safety. Acta Biomater. 27 (2015), 179–193.
24. Wang, J., Yang, G., Guo, X., Tang, Z., Zhong, Z., Zhou, S., Redox-responsive polyanhydride micelles for cancer therapy. Biomaterials 35 (2014), 3080–3090.
25. Lin, T.Y., Li, Y., Liu, Q., Chen, J.L., Zhang, H., Lac, D., Zhang, H., Ferrara, K.W., Wachsmann-Hogiu, S., Li, T., Airhart, S., White, R.D., Lam, K.S., Pan, C.X., Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials 104 (2016), 339–351.
26. Ding, J., Shi, F., Xiao, C., Lin, L., Chen, L., He, C., Zhuang, X., Chen, X., One-step preparation of reduction-responsive poly(ethylene glycol)-poly(amino acid)s nanogels as efficient intracellular drug delivery platforms. Polym. Chem. 2 (2011), 2857–2864.
27. Ding, J., Chen, J., Li, D., Xiao, C., Zhang, J., He, C., Zhuang, X., Chen, X., Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy in vitro. J. Mater. Chem. B 1 (2013), 69–81.
28. Ding, J., Shi, F., Li, D., Chen, L., Zhuang, X., Chen, X., Enhanced endocytosis of acid-sensitive doxorubicin derivatives with intelligent nanogel for improved security and efficacy. Biomater. Sci. 1 (2013), 633–646.
29. Chen, J., Ding, J., Zhang, Y., Xiao, C., Zhuang, X., Chen, X., Polyion complex micelles with gradient pH-sensitivity for adjustable intracellular drug delivery. Polym. Chem. 6 (2015), 397–405.
30. Wei, W., Yue, Z.G., Qu, J.B., Yue, H., Su, Z.G., Ma, G.H., Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation. Nanomedicine 5 (2010), 589–596.
31. Shin, K., Lim, A., Odegaard, J.I., Honeycutt, J.D., Kawano, S., Hsieh, M.H., Beachy, P.A., Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol. 16 (2014), 469–487.
32. Shin, K., Lim, A., Zhao, C., Sahoo, D., Pan, Y., Spiekerkoetter, E., Liao, J.C., Beachy, P.A., Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26 (2014), 521–533.
33. Li, P., Zheng, Y., Ran, H., Tan, J., Lin, Y., Zhang, Q., Ren, J., Wang, Z., Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice. J. Control. Release 162 (2012), 349–354.
34. Ding, J., Li, C., Zhang, Y., Xu, W., Wang, J., Chen, X., Chirality-mediated polypeptide micelles for regulated drug delivery. Acta Biomater. 11 (2015), 346–355.
35. Shen, Y., Fu, X., Fu, W., Li, Z., Biodegradable stimuli-responsive polypeptide materials prepared by ring opening polymerization. Chem. Soc. Rev. 44 (2015), 612–622.
36. Eckmann, D., Composto, R., Tsourkas, A., Muzykantov, V., Nanogel carrier design for targeted drug delivery. J. Mater. Chem. B 2 (2014), 8085–8097.
37. Wang, X., Zhang, J., Wang, Y., Wang, C., Xiao, J., Zhang, Q., Cheng, Y., Multi-responsive photothermal-chemotherapy with drug-loaded melanin-like nanoparticles for synergetic tumor ablation. Biomaterials 81 (2016), 114–124.
38. Xu, X.D., Cheng, Y.J., Wu, J., Cheng, H., Cheng, S.X., Zhuo, R.X., Zhang, X.Z., Smart and hyper-fast responsive polyprodrug nanoplatform for targeted cancer therapy. Biomaterials 76 (2016), 238–249.
39. Cheng, Z., Al Zaki, A., Hui, J.Z., Muzykantov, V.R., Tsourkas, A., Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338 (2012), 903–910.
40. Chen, J., Ding, J., Xiao, C., Zhuang, X., Chen, X., Emerging antitumor applications of extracellularly reengineered polymeric nanocarriers. Biomater. Sci. 3 (2015), 988–1001.
41. Hu, S., Lee, E., Wang, C., Wang, J., Zhou, Z., Li, Y., Li, X., Tang, J., Lee, D.H., Liu, X., Shen, Y., Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy. J. Control. Release 220 (2015), 175–179.
42. Zhang, R.W., Li, Y.F., Cai, Q.Y., Liu, T.P., Sun, H., Chambless, B., Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother. Pharmacol. 41 (1998), 257–267.
43. Sahay, G., Alakhova, D.Y., Kabanov, A.V., Endocytosis of nanomedicines. J. Control. Release 145 (2010), 182–195.
44. He, L., Huang, Y., Zhu, H., Pang, G., Zheng, W., Wong, Y.S., Chen, T., Cancer-targeted monodisperse mesoporous silica nanoparticles as carrier of ruthenium polypyridyl complexes to enhance theranostic effects. Adv. Funct. Mater. 24 (2014), 2754–2763.
45. Barrett, T.L., Smith, K.J., Hodge, J.J., Butler, R., Hall, F.W., Skelton, H.G., Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. J. Am. Acad. Dermatol. 37 (1997), 430–437.
46. Sherr, C.J., G1 phase progression - Cycling on cue. Cell 79 (1994), 551–555.
47. King, R.W., Jackson, P.K., Kirschner, M.W., Mitosis in transition. Cell 79 (1994), 563–571.
48. Zhong, W., Peng, J., He, H., Wu, D., Han, Z., Bi, X., Dai, Q., Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin. Invest. Med. 31 (2008), E8–E15.
49. Xie, J.H., Hollande, F., Haynes, J.M., Pouton, C.W., Ventura, S., Troubleshooting immunohistochemical labelling of proliferating cell nuclear antigen (PCNA) in cryocut tissue sections of mouse prostate. J. Pharmacol. Toxicol. 61 (2010), 98–101.